The Association Between Effectiveness and Study Design Among Psychedelic Research for Patients with Clinical Depressive Symptoms: A Systematic Review and Meta-analysis
Abstract
Psychedelics, such as psilocybin and MDMA, have shown promising efficacy in the treatment of major depressive disorder (MDD). Research studies have demonstrated that these substances, when administered in controlled therapeutic settings, can induce profound and positive changes in mood, perception, and cognition. Psilocybin, a naturally occurring psychedelic compound found in certain mushrooms, has been investigated for its ability to alleviate depressive symptoms. Clinical trials involving psilocybin-assisted therapy have reported significant and sustained improvements in mood and overall well-being among individuals with MDD. The compound is believed to work by promoting neuroplasticity and fostering a deepened introspective experience, leading to increased self-awareness and emotional healing. MDMA, commonly known as ecstasy, has also shown therapeutic potential for MDD. In controlled settings, MDMA-assisted psychotherapy has demonstrated effectiveness in reducing symptoms of depression and promoting emotional openness. The drug's empathogenic properties may enhance the therapeutic alliance between the patient and therapist, facilitating a more profound exploration of underlying psychological issues. However, it is important to note that the current body of research on psychedelic therapy for clinical depressive symptoms is characterized by high heterogeneity due to the use of different psychedelics and varied study designs. The aim of our study is to examine whether the effectiveness of each category of psychedelic drug is associated with distinct study designs. Eligibility Criteria Eligible studies were clinical trials in adult patients (≥18 years) with clinical depression such as distress related to life-threatening diagnoses and terminal illness, MDD, or other psychiatric disorders with comorbid clinical depression. We considered clinical trials with the following study designs, including blinded randomized controlled trials (RCTs), open-label RCTs, and single-arm pre-post studies. We excluded follow-up studies (follow-up after trial completion) and studies with healthy volunteers. We also excluded conference abstracts, editorials, reviews, meta-analyses, case reports, and case series, as well as publications reporting duplicate data. Data Sources and Search Two reviewers independently searched MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL), EMBASE, ClinicalTrial.gov, and PubMed without language restrictions. We also searched grey literature and reviewed reference lists of included studies and related systematic reviews.10 Study Selection and Data Extraction Two reviewers independently screened titles, abstract, and full-text articles. Reviewers resolved disagreements by discussion and, if necessary, by consulting corresponding authors. Two reviewers independently extracted data and discrepancies were resolved by consensus and, when necessary, by consulting corresponding authors. We extracted the study-level variables, such as author, year, condition, and dose of psychedelic drugs. Statistical analysis Random-effects meta-analysis was performed. Meta-regression and subgroup analysis was performed if feasible. Publication bias analysis was also performed if feasible.
Topics & conditions
Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.
Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.